LOX-1 Inhibition After Heart Attack: Phase 2 Trial Results

Navigating Potential conflicts of Interest in Cardiovascular Research: A Transparency Report

Understanding potential conflicts⁢ of interest is crucial for ⁣maintaining the integrity and trustworthiness⁢ of medical research. It’s vital ‌for you, as a healthcare ‍professional or interested reader, too be aware of affiliations that could influence study outcomes. This report details‍ relevant financial relationships disclosed by the authors of a recent cardiovascular study, ensuring full transparency.

Here’s a breakdown of the disclosed relationships, categorized​ for clarity:

1. Direct Employment & Stock Ownership:

*⁤ AstraZeneca: Several authors have current or former ties to⁤ AstraZeneca. Specifically,⁢ .K., A.C., A.L.V., and M.T. are current AstraZeneca ​employees and hold stock options within the company. Additionally, A.G.was formerly a full-time employee of AstraZeneca and is now with Ribocure Pharmaceuticals,where they also hold stock.
* Regeneron Pharmaceuticals: R.G. currently works at Regeneron Pharmaceuticals‍ and maintains stock ownership in both AstraZeneca and Regeneron.

2. ⁣Research Funding & Grants:

* ‍ Multiple ⁢Sources: A notable number of authors ‌(M.L.O.D., D.A.M.,M.S.S., J.K., J.-G.P., and S.A.M.) have received ​research grant⁢ support through Brigham and Women’s Hospital from a broad ‍range of pharmaceutical companies.‌ These include⁤ Abbott, Amgen, Anthos Therapeutics, AstraZeneca, Boehringer Ingelheim, Daiichi-Sankyo, Ionis, Marea, Merck, Novartis, Pfizer, Saghmos Therapeutics, and Verve Therapeutics.
* Specific Grants: J.S. has received research grant support from Biotronik, Sanofi, Pfizer, and Attralus. J.A.C.L.reports grant funding from AstraZeneca and Canon Medical Systems. B.F. received grant support from ⁢AstraZeneca/Medimmune, MedTrace, Ionis, and the NIH/NHLBI.M.T.L. has received research funding through⁣ Massachusetts General Hospital from astrazeneca,the American⁤ Heart association,Ionis,Johnson & Johnson Innovation,MedImmune,the National⁤ Academy of Medicine,the National Heart,Lung,and Blood Institute,and the Risk Management Foundation of the Harvard Medical Institutions.
* Novartis & Other Grants: A.Z. has⁣ received grant support ⁢from novartis. J.L.-S. reports research grants from AstraZeneca, Bayer/Johnson‍ & Johnson, Pfizer, and Amgen.

3.Consulting Fees & Speaker Honoraria:

* extensive ⁢Consulting: ‍ J.S. has received consulting fees from BMS, Sanofi, and Attralus. E.K. reports extensive consulting fees and/or research funding ‌from numerous companies, including⁤ Boehringer Ingelheim, Bayer, Novo Nordisk, ​Daiichi-Sankyo, Abbott, Ono Pharmaceutical, and ⁣Tanabe-Mitsubishi.
* Diverse Consulting Roles: M.L.O.D., D.A.M.,M.S.S., J.K., J.-G.P., and S.A.M. have received⁢ consulting fees‌ from a wide array of companies, including Amgen, AMPEL‍ BioSolutions, Anthos Therapeutics, AstraZeneca, Beren Therapeutics, Boehringer Ingelheim, Dr.Reddy’s Laboratories, Fibrogen, Merck, Moderna, Novo ‌Nordisk, Precision BioSciences, and Silence Therapeutics.
* ⁣ Specific Consulting Relationships: A.Z. has received consulting and/or ‍lecture fees from AstraZeneca, novartis, Boehringer ‍Ingelheim, Amarin, pfizer,⁢ Sanofi, ⁢Amgen, Eli Lilly, and Novo Nordisk. A.A.D.P.F. reports consulting fees​ from AstraZeneca, Novartis, Boehringer ⁤Ingelheim, Merck Sharp Dohme, and Mundipharma.
*‌ Speaker Honoraria: J.L.-S.has received speaker honoraria from Menarini.‌ J.S. also received speaker bureau fees‌ from Pfizer, AstraZeneca, ⁤Boehringer Ingelheim, Novartis, Bayer, Sanofi, Biotronik, CircleCVi, Takeda, Amicus, ⁤and BMS.

4.Lecture Fees:

* Numerous Engagements: E.K. reports‌ receiving lecture fees